Published in final edited form as:

Drugs Future. 2012 March 1; 37(3): 183–196.

Zinc Finger Nucleases: Tailor-made for Gene Therapy

S.-T. Chou^{1,2}, Qixin Leng¹, and A. J. Mixson¹

¹Department of Pathology, University of Maryland School of Medicine, MSTF Building, 10 South Pine Street, Baltimore, MD 21201, USA

²Department of Chemical and Biomolecular Engineering, University of Maryland, College Park, MD 20742

Abstract

Genome editing with the use of zinc finger nucleases has been successfully applied to variety of a eukaryotic cells. Furthermore, the proof of concept for this approach has been extended to diverse animal models from *Drosophila* to mice. Engineered zinc finger nucleases are able to target specifically and manipulate disease-causing genes through site-specific double strand DNA breaks followed by non-homologous end joining or homologous recombination mechanisms. Consequently, this technology has considerable flexibility that can result in either a gain or loss of function of the targeted gene. In addition to this flexibility, gene therapy by zinc finger nucleases may enable persistent long term gene modification without continuous transfection- a potential advantage over RNA interference or direct gene inhibitors. With systemic viral delivery systems, this gene-editing approach corrected the mutant factor IX in models of mouse hemophilia. Moreover, phase I clinical trials have been initiated with zinc finger nucleases in patients with glioblastoma and HIV. Thus, this emerging field has significant promise as a therapeutic strategy for human genetic diseases, infectious diseases and oncology. In this article, we will review recent advances and potential risks in zinc finger nuclease gene therapy.

Discovery of Zinc Finger Nucleases and Its Components

Homologous recombination (or homology-directed repair, HDR) is a powerful gene targeting technique in which DNA sequences are transferred from one sister chromosome to another (1). A particular gene may be corrected or inactivated in cells or living organisms by this type of genetic recombination. However, the frequency of HDR, particularly in higher eukaryotic cell, is as low as one per million treated cells. Nevertheless, double stranded breaks (DSB) can stimulate recombination efficiency several thousand-fold, approaching gene targeting frequencies as high as 29% without selection. A method that induces a DSB at a specific site will promote the frequency of gene targeting and potentially have significant therapeutic utility (2–4). The need for such an approach spurred the development of zinc finger nucleases.

Each subunit of the zinc finger nuclease (ZFN) is composed of three domains: 1) a non-sequence-specific cleavage domain at the C-terminal mediated by *FokI* nuclease, 2) a DNA binding zinc finger domain, Cys₂-His₂ (C2H2), at the N-terminal, essential for its specificity, and 3) a peptide linker that connects the zinc finger domain with the nuclease. The restriction enzyme *FokI* (5, 6) induces a DNA double strand break as a catalytic dimer. Thus, for DNA cleavage to occur, two zinc finger subunits must bind to the gene target sequence in the opposite orientation leading to *FokI* dimerization (Fig. 1). In addition to its

nuclease activity, effects of engineered zinc fingers on DNA extend to artificial transcription factors (7) and methylases (8).

The zinc finger motif was first discovered in transcription factor IIIA (9) and exhibited specific DNA-binding in eukaryotic cells (10, 11). The binding domain of the zinc finger can insert its alpha-helix into the major groove of DNA in a sequence-specific manner (12, 13). Currently, the C2H2 zinc finger is the most common DNA binding domain in humans with nearly 1000 different zinc finger motifs identified in transcription factors. This predominance in nature to bind specifically to DNA sequences provides the framework for their therapeutic use. Moreover, linking different zinc fingers together in a subunit has enabled investigators to design targeted ZFN specifically to almost any gene. Unfortunately, it is not usually possible to link different zinc fingers together based on their 3-base pair recognition code, because of interfinger dependence, which may alter the base-pair specificity of the zinc finger subunit.

With each finger recognizing ~three base pairs (bp), a three-finger subunit of ZFN binds to 9 base pairs on the DNA. Typically, two ZFN subunits containing 6 to 12 zinc fingers (or 3 to 6 zinc finger pairs), respectively, bind to between 18 and 36 nucleotides. Several studies have indicated that ZFN with a higher number of zinc fingers (4, 5, and 6 finger pairs) have increased specificity (14, 15). Comparison of a pair of 3-finger ZFNs and a pair of 4-finger ZFNs detected off-target cleavage in human cells at 31 loci for the 3-finger ZFNs and at 9 loci for the 4-finger ZFN (15). In some cases, however, the activity of ZFN may be reduced with 5- and 6-paired ZFN compared to 3- or 4-paired ZFN (16). Moreover, Guo and colleagues found that subunit affinity for the DNA sequence was critical in determining the ZFN activity and may be more important than the number of fingers: that is, the subunits with lowest and highest binding affinity had reduced activity compared to the subunit with intermediate activity (17).

Mechanism of Gene Modification

The DNA double strand break (DSB), induced by ZFN at endogenous loci, can be repaired primarily by two pathways in eukaryotic cells: error-prone non-homologous end joining (NHEJ) or homology-directed repair (HDR) in the presence of a donor DNA (Fig. 1) (18–22). Because small base-pair insertions or deletions can be directly induced by the NHEJ driven-DNA repair process, knockout of specific genes within eukaryotic cells can be readily achieved by this ZFN-mediated approach. More complicated modifications of DNA may also be accomplished by ZFN with the NHEJ pathways. For example, with two pairs of ZFN, large deletions of 15 megabases occurred efficiently (23). For HDR modifications, single or multiple transgenes can be introduced into the DSB site by co-expression of ZFN and donor DNA. With donor DNA homologous to the sequences flanking the DSB, HDR mediated by ZFN can be quite versatile, including insertion of marker genes, replacement of mutant with wild-type genes, or insertion of different transgenes at the same or different loci on chromosomes. Although the NHEJ pathway can be used in all eukaryotic cells without extensive knowledge of the sequence of the targeted gene, HDR can be used in eukaryotic cells/organisms in which the gene sequence of the targeted locus is known. The option of utilizing a selection marker as part of donor DNA can be advantageous for HDR, particularly if target modification with zinc fingers is quite low. Moreover, NHEJ occurs primarily in G1 of the cell cycle, whereas HDR occurs primarily in G2. Consequently, HDR activity of ZFN was increased by 7-fold in cells treated with vinblastine, which increased their number in G2 (24). Whether the activity of NHEJ is altered by cell cycle agents that increase transit time or cause G1 arrest has not been reported. Nevertheless, lower temperatures of 30°C may increase ZFN activity, presumably by NHEJ, although the

mechanism has not been established (25, 26). These post-DSB DNA repair mechanisms have been comprehensively reviewed (27).

Selection of ZFN domain

Since the DNA binding domain of ZFN is essential for site-specific cleavage, advances in generating ZFN have continued with six strategies developed thus far. These include modular assembly (12, 28), sequential context-sensitive selection (29–32), bipartite library strategy (33), oligomerized pool engineering (OPEN) (34, 35), the context-dependent assembly (CoDA) (36), and the “2 + 2” approach (see Table I) (27, 37, 38). Because development of ZFNs require specific libraries and are labor-intensive, several academic laboratories formed the Zinc Finger Consortium and have as their objective the widespread use of ZFN amongst investigators (e.g., ZiFiT software, screen DNA for potential ZFN (39); specific ZFN protocols (<http://www.zincfingers.org/>) and plasmids encoding ZFN are available through or linked to this website. Although ZFN strategies have been extensively discussed, we briefly summarize a few of these methodologies .

1. Modular assembly (12, 28) is a parallel selection method, that uses a phage display system (40). This is the earliest ZFN approach and identifies a single finger triplet that targets base-pair sequences individually from a large ZF archive and links them to form zinc finger proteins. Zinc finger domains have been revealed that bind to most sequences of 5'-GNN-3', 5'-ANN-3', and 5'-CNN-3' (14, 41, 42). Although the modular assembly is relatively simple and reveals efficient DNA binding activity in lower eukaryotic cells, some studies showed reduced sequence specificity and binding affinity associated with lower efficacy and higher toxicity, compared to more recently developed approaches (see Table I) (43, 44).
2. Oligomerized Pool Engineering (OPEN) is a robust and sensitive ZFN design strategy (34). This approach, supported by the Zinc Finger Consortium, involves screening previously characterized ZFN for each target DNA triplet, followed by random PCR assembly and selection with the bacterial-two-hybrid system. Since three zinc fingers are selected simultaneously, the optimized ZFN binds efficiently to the target gene (34, 35). The ZFNs developed by the OPEN method are highly specific for the target DNA, but this approach is still labor-intensive and requires significant expertise.
3. Most recently, the context-dependent assembly approach (CoDA) has been developed, also by investigators (36) associated with the ZF consortium. The group assembled 181 3-zinc finger arrays with known 9-bp target sites. To obtain the desired ZFN subunit with new DNA specificity, two different zinc finger arrays with a common middle finger have their first fingers and the third fingers exchanged. Nearly 75% of these zinc finger nucleases activated the bacteria two-hybrid more than 3-fold, indicating a high likelihood of site-specific cleavage. Indeed, when tested *in vivo*, the success rate per target for obtaining NHEJ-driven mutations with CoDA-generated ZFNs was 50% in zebrafish and plants, which was similar to success rate of the OPEN-generated ZFN (36). Compared to the OPEN-approach, the CoDA may be slightly less specific, but it is significantly easier to develop. Of the methods discussed, this provides the investigator the best opportunity to develop a functional ZFN in a cost effective manner.
4. In addition to these strategies, Sangamo Biosciences has developed a proprietary method (“2 + 2”) in which investigators can obtain a tailor-made ZFN either through collaboration or through purchasing from Sigma-Aldrich (CompoZr® Custom ZFN Service). Sigma-Aldrich/Sangamo Bio has constructed ZFNs that target a large number of different genes. The “2+2” method involves two steps in

which promising lead 4 zinc finger nuclease subunits assembled from an archive of pre-existing 2-finger units with known DNA specificities are used, with further optimization done with a proprietary algorithm (24)(see review of different approaches by(37)). Sigma-Aldrich through the CompoZr Custom Service offers an extensive list of ZFN targeting genes, but the disadvantage of these ZFNs are their costs (www.sigmaaldrich.com/life-science/zinc-finger-nuclease-technology/knockout.html).

Cells and Model Organisms

We have divided the applications of ZFN into utilitarian and disease-relevant applications. We are aware that such divisions are somewhat arbitrary since the ZFN methods relevant for non-disease subjects have been applied to human-diseases. Moreover, this review primarily examines the importance of ZFN and its application to animal models, but importantly this technology has also been established in plants including *Zeamays* (45), tobacco (46), and *Arabidopsis* (47). As the global food crisis has become a serious issue, there is expectation that genetic modification of crop plants with this technology will improve agricultural productivity by enhancing stability of crop yield and tolerance to herbicides.

Utilitarian/Non-disease Applications

In vitro and *In vivo* Models

CHO Cells—NHEJ-mediated target gene knockout is the most common approach in non-primate mammalian cells, by transfection of plasmids containing ZFNs (see Table I). Several genes have been modified by this approach with a frequency up to 30% in Chinese hamster ovary cells, including dihydrofolate reductase (48, 49), *BAK/BAX* (50), glutamine synthetase (*GS*) (49), and α -1,6-fucosyltransferase (49, 51). In contrast to siRNA, transient intracellular increases of ZFN are sufficient to induce permanent knockouts in both alleles.

The NHEJ pathway is independent of the homologous recombination donors, thereby making it the preferred approach for unsequenced genomes such as those in CHO cells. The simplicity of this mechanism allows the ZFN to generate multiple gene knockouts simultaneously in the same cell. For example, knockout of dual pro-apoptotic genes (*BAK* and *BAX*) in CHO cells has been shown to increase the viability of the cells while grown in a large scale bioreactor. Such customized cell lines may be used by the pharmaceutical industry to increase therapeutic peptides/proteins. Table 1 lists ZFN-mediated gene modification in various eukaryotic cells and organisms.

Non-Stem Human Cells—Although NHEJ or HDR may be used in human cells, only the HDR method has been used to insert donor homologous DNA into specific loci of the chromosome. In addition to different disease targets, NHEJ and HDR methods have been applied to several human somatic cells, including human embryonic kidney (HEK) 293 cells (24, 34, 52–55), K562 cells (24, 34, 53), and T cells (24, 56).

To enhance the efficacy of ZFN technology *in vitro* and *in vivo* requires increasing efficiency of gene targeting. Nonetheless, there have been significant advances in this field. Until recently, insertion of donor DNA was restricted to large arm lengths (~1.5 kb, 0.75 kb/arm), which delayed the experimental output until entire loss of donor plasmid expression. More recently, Orlando et al. (57) demonstrated that ZFN-driven transgene integration with a donor as small as 100 bp of chromosomal homology could be generated at a frequency of 10% using a synthetic oligonucleotide. By improving the specificity of the “2 + 2” (24) and engineered OPEN ZFN approaches (34), gene targeting frequency has been enhanced to

20% and 50% respectively. The success of gene addition *in vitro* suggests that ZFN approaches may be effective *in vivo*.

ZFN also has an important role in targeting dynamic biological processes that occur in a cell. Using a ZFN-mediated approach, Doyon and colleagues fused fluorescent markers in-frame with genes of interest in mammalian cells to study the function and location of proteins essential in clathrin-mediated endocytosis. Compared to the randomly inserted over-expressing transgenes, ZFN-mediated genome editing in which the stoichiometry of clathrin light chain A and dynamin 2 is preserved proved important for understanding the dynamics of endocytosis (25). Indicative of a highly efficient endocytic process, the use of ZFN-modified cells showed that clathrin was down-regulated with recruitment of dynamin to vesicles; in contrast, cells in which the gene constructs were randomly inserted showed the likely artifact of co-localization of the two proteins in vesicles. The ability to add a marker and/or to mediate gain or loss of function of gene makes ZFN a very powerful tool for understanding the role of proteins in biological processes (see p53 gain of function in Cancer Disease Section below.)

Human Stem Cells—Aberrant human stem cells, obtained from patients with genetic heritable disorders, are potential candidates for gene editing as they can differentiate, propagate, and restore normal tissue function. Whereas the application of stem cells for gene and cell therapies draws much attention, the lack of precise gene targeting to disease-linked allele as well as efficient exogenous transgene integration have been major challenges to stem cell-based therapies.

Non-dividing human stem cells are difficult to transfect compared to somatic cells. To co-deliver ZFN and donor DNA efficiently into human stem cells, lentivirus has been applied for cell transduction. Based on low background integration of integrase-defective lentiviral vectors (IDLV), transient expression of ZFN was able to induce site-specific integration. Gene addition at chemokine (C-C motif) receptor 5 (*CCR5*) loci had a 5% success rate in CD34⁺ hematopoietic stem/progenitor cell (HSPC)(58). In another study with lentivirus, investigators were able to target the safe harbor *AAVS* locus efficiently with ZFN in both human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) (59). Although IDLV appear relatively safe, non-specific random integration remains a potential risk.

Electroporation has also been utilized to deliver ZFN to hESCs and hiPSC. With electroporation, successful gene-insertion at the *OCT4* and *PITX3* loci (59) and gene-correction of GPI-AP (60) was achieved in human stem cells. Neither karyotypic abnormalities nor effects on pluripotency were observed in HDR-driven gene addition. Holt and colleagues have also used electroporation in CD34⁺ HSPC to disrupt the *CCR5* gene, with a frequency of 17% (61). Moreover, the use of ZFN to insert a site-specific reporter into stem cells has recently been suggested as a means to study their lineage in disease progression (62).

Although ZFN provides an alternative for gene targeting, technical challenges in stem cell biology are significant. For example, cell culture conditions for these cells have an important role in determining the precision and stability of DSB repair (63).

Drosophila Melanogaster* and *Caenorhabditis elegans

Germline and somatic cells of *D. Melanogaster* (5) and *C. elegans* (64) were among the earliest models used to study gene disruption with ZFN (see Table I). A group led by Carroll used ZFN to target efficiently several loci of genes in flies by embryonic injection (65–68). The results indicated that ZFNs were capable of inducing mutant offspring from half or

more of the parents, and that mutant offspring represented approximately 10% of all offspring. These studies with *Drosophila* also provided greater insight into mechanisms of DNA repair. When different forms of donor DNA (linear vs. circular plasmids) were compared, HDR occurred most efficiently with co-injection of the circular donor plasmid and ZFN mRNA. Notably, Carroll's lab found that in the absence of ligase IV, the frequency of HDR compared to NHEJ increased to nearly 100% (68). A more recent study determined that the synthesis-dependent strand annealing mechanism has a significantly greater role in HDR repair compared to the single strand annealing one (69).

Embryo Injection and Cloning: From Zebrafish to Pigs

The zebrafish is a non-mammalian vertebrate model that has been studied for decades. Because of its transparent embryo and forward genetics, the zebrafish is an ideal candidate for gene modification with engineered ZFN *in vivo*. Gene disruption in zebrafish has been investigated with mRNA injection of one-cell embryos. Four-finger ZFN that targeted the golden loci (eye color) generated at least 30% mutant phenotypes in the injected embryo while ZFN targeting the no tail (*ntl*) loci generated mutations in the germ line with an average frequency of 20%. Another context-dependent bacterial one-hybrid ZFN that targeted the vascular endothelial growth factor receptor-2 (32) resulted in insertions or deletions with 20% frequency. Recently, Foley and colleagues validated the OPEN-engineered ZFN approach in zebrafish by efficiently modifying five genes (*tfr2*, *dopamine transporter*, *telomerase*, *hif1aa*, and *gridlock*)(35).

Injection of embryos with ZFN encoding mRNA can also be applied to mammals such as rats and mice that are genetically closer to humans. Numerous gene knockout rats (*IgM*, *Rab38* and *IL2R*-) (70, 71) and mice (*Mdr1a*, *Jag1*, *Notch3*) (72) have been generated through an NHEJ mechanism. By circumventing embryonic stem (ES) cells, germ line transmission of modified alleles can be accomplished in offspring more efficiently. Before using the ZFN approach, knockout rats were very difficult to generate. More recently, HDR-mediated target integration in rats and mice embryos has been recently reported (73, 74). These studies showed that mutant or wild-type animals can be developed by inserting the gene modification into an endogenous locus. Similar ZFN methods targeting the embryonic loci of immunoglobulin M (*IgM*) generated knockout rabbits with deficient serum *IgM* (75); approximately 30% of the founder rabbits had a mutation at the *IgM* locus. In addition, homologous recombination with a neomycin gene was successful in 20% of the fetuses at the *IgM* locus.

Despite the success of injecting ZFN mRNA directly into the embryos of many species, this approach has not been successful with larger domestic animals. Nevertheless, somatic cell nuclear transfer (SCNT) with ZFN has been an effective approach with which to knockout several genes (peroxisome proliferator-activated receptor-gamma, beta-lactoglobulin, and -1,3-galactosyltransferase) in pigs and cattle (76–78). Such knockouts may prove important for human health and for agriculture. For example, beta-lactoglobulin, which is a major allergen in the milk of cattle, was knocked out by this method with apparently healthy cattle produced. Although inactivation of genes in larger domestic animals has been done with homologous recombination strategies, the approach with SCNT and zinc fingers makes such gene knockouts far more feasible and easy to perform.

Specific Disease Based Therapies

HIV—One of the major co-receptors for HIV-1 entry, chemokine receptor 5 (*CCR5*), has been targeted by several gene-inhibitory approaches including RNAi (79, 80), anti-CCR ribozymes (81, 82), and most recently by ZFN. The specificity and efficiency of *CCR5*-targeted ZFN has been studied in mammalian cells (55) and human stem cells (58). ZFN-

mediated *CCR5* disruption in human CD4⁺ T cells, which resulted in HIV-1 resistance, was the first demonstration of ZFN as an anti-HIV agent (56). By transplanting ZFN-modified human CD4⁺ T cells in which more than 50% of the *CCR5* gene was disrupted, the therapeutic potential of these modified cells was validated by marked reduction of viral titers in the plasma 50 days post HIV infection in a mouse model. These findings in a mouse model have resulted in testing the efficacy of ZFN-targeting the *CCR5* gene *ex vivo* in three phase I clinical trials (ClinicalTrials.gov Identifier: NCT00842634, NCT01044654, NCT01252641).

Two recent studies advanced the use of ZFN to enhance augmentation and duration of natural immunity to HIV-1 infection. The multipotency of human CD34⁺ hematopoietic stem/progenitor cells (HSPC), which give rise to myeloid and lymphoid cell lines, may create a greater opportunity than use of T cells for reducing of HIV infection. Transplantation of *CCR5*-ZFN treated HSPC showed a persistent and stable HIV-resistant phenotype for more than 10 weeks, indicating long-term control of virus replication and reconstitution of the immune system (61). Nevertheless, *CCR5*-suppressed T cells are still vulnerable to infection by other strains of the HIV virus. As a result, ZFN targeting an HIV associated surface receptor *CXCR4* was investigated. CD4⁺ T cells treated with ZFN targeting *CXCR4* were observed to have similar therapeutic effects against *CXCR4* tropic HIV without significant loss of cell viability (83). Therefore, the goal to optimize HIV resistance by disruption of both *CCR5* and *CXCR4* in human T cells appears to be promising and within reach.

Heritable diseases-Ex Vivo Approach—The development of ZFN optimization and selection in human stem cells has resulted in a number of studies targeting aberrant genes of inherited monogenetic disorders with wild-type donor DNA, leading to reversal of disease. Among these studies, ZFN targeting the *IL2R*- locus important in X-linked severe combined immune deficiency (X-SCID) has been extensively studied. By using ZFN and wild-type donor DNA, Urnov and colleagues were able to correct 7 % of an exon 5 mutation in the *IL2R*-locus of both X-chromosomes in K562 cells; this resulted in normal mRNA and protein levels of *IL2R*- (24). In CD4⁺ cells, they determined that ZFN-mediated correction of a GFP mutant located in the *IL2R*-locus occurred at a 5.3 % frequency. These ZFN models targeting the *IL2R*- locus indicate that this strategy may be effective in treatment of X-SCID patients. By modifying the CD4⁺ cells before expansion and re-injection of these modified cells, the ZFN approach has advantages over random viral insertion into chromosomes that may result in insertional oncogenesis.

Induced pluripotent stem cells (iPSCs) derived from sickle cell anemia (84, 85) and X-linked chronic granulomatous disease (X-CGD) (86) patients have been treated by ZFN to correct disease-causing alleles. Targeted integration of the *-globin* gene to correct the sickle cell mutation in human iPSCs had success rates up to 40%, without significant off-target effects. Pluripotency was retained in gene-corrected, transgene-removed iPS cell lines. Furthermore, ZFN targeting the safe harbor *AASV1* locus in X-CGD iPSC successfully inserted the gp91 transgene (86). Neutrophils differentiated from these treated X-CGD iPSC had functional phenotypes similar to normal neutrophils. Nevertheless, scale-up and transplantation of iPSC-derived cells present challenges before this therapy can be used clinically.

Hemophilia-In Vivo Approach—Hemophilia B is a X-linked genetic disorder in which the liver produces inadequate levels of factor IX for clotting. Numerous strategies for preclinical and clinical gene therapy have been tried, most of which have failed because of inadequate, long-lasting production of factor IX. The ZFN approach has considerable promise for this disease in that the mutant factor IX loci can be targeted and replaced with

the wild-type sequence (87). By using a hepatotropic adeno-associated virus (AAV), the factor-IX specific ZFN was systemically delivered to a humanized mouse model with factor IX deficiency. ZFN-driven gene correction specifically replaced the mutated Factor IX gene with a wild-type gene that resulted in persistently restored coagulation function for more than 30 weeks, whereas the control mice in which AAV carrying factor IX was used had elevated levels for only 6 weeks. In contrast to the *ex vivo* cell manipulation, which cannot be easily applied to this disease, this study indicates that systemic delivery with ZFN by HDR can effectively target the hepatocyte *in vivo*. Although this approach was highly specific, the ZFN did have at least one off-target site and AAV was integrated at several sites in the genome. The mice showed no effects on growth or weight over an 8 month period, however. In addition to Factor IX deficiency, this study has important implications for diseases of the liver from heritable disorders to infectious diseases.

Cancer—Cancer genes and the pathways they regulate have been identified and characterized over the past several decades. Oncogenes and mutant tumor suppressor genes clearly provide an opportunity for the use of ZFN-mediated approach. Indeed, ZFNs have been used to down-regulate specific growth factors or replace *p53* mutations. In targeting the tumor angiogenic factor *VEGF-A*, an OPEN-driven ZFN strategy induced gene alteration with 7.7 % and 54% efficiency, respectively, in K562 cells treated with and without vinblastine (34). Although vinblastine was associated with significant toxicity in these cells, other agents that arrest G2 may increase ZFN efficacy with less cellular toxicity.

Furthermore, a yeast-one-hybrid four-finger ZFN was designed to replace mutant *p53* with wild-type *p53* in two cancer cell lines (26). With a liposomal delivery system, the apparent success rate was about 0.1%. Although the homologous recombination events were not particularly effective in this case, modifications at the *p53* and *VEGF-A* loci provide the framework for further investigation. A more efficient delivery system may be more effective than the liposome carriers for these *p53 in vitro* systems. Alternatively, a more active *p53*-targeting ZFN would also be attractive particularly for less efficient but safer liposomal or peptide delivery systems.

In addition to modifying cancer cell genes, investigators have utilized ZFN to augment T-cell mediated antitumor therapy. The therapy is based on two results: 1) apoptosis is induced by glucocorticoids on cytolytic T-lymphocytes (CTLs) of glioblastoma patients (88, 89) and 2) IL-13 zetakine-expressing CTLs induced significant cell death of glioblastomas in an animal model (90). To prevent apoptosis of “zetakine” expressing CTL in patients that are administered steroids, Reik and colleagues knockdown the glucocorticoid receptor in the modified CTLs with ZFN. Consequently, the cytolytic activity of the “zetakine” expressing CTLs toward glioblastomas was retained in the presence or absence of treatment with glucocorticoids (91). This achievement in an animal model was a pioneering study that has now been translated into the clinic (phase 1; ClinicalTrials.gov Identifier NCT01082926).

Infectious Diseases—Direct inactivation of episomal DNA of infectious viruses is another feasible target. The formation of covalently closed, circular double stranded DNA (cccDNA) occurs in hepatocytes infected with Hepatitis B virus (HBV). Currently, there are no therapies that have focused on targeting cccDNA, which may be one reason why more than 50% of treated hepatitis patients fail therapy. Cradick and colleagues developed an HBV-specific ZFN that inactivated at least 36% of the episomal DNA and reduced 30% of pregenomic RNA in hepatoma cells transfected with plasmid containing the HBV genome (92). This study provides proof of principle that ZFN-induced DSB in episomal viral DNA, and further reduction is anticipated when viral vectors replace the liposomal carrier that was used in the above study.

The ZFN approach has been suggested as a treatment for malaria. Carried by a cell penetration peptide (CPP), the ZFN has been hypothesized to be delivered to infected red blood cells to target the *Plasmodium* genome (93). This approach may result in functional gene knockout in the parasite and lead to the death of *Plasmodium* if the delivery system is effective.

ZFN Delivery

To manipulate gene expression, an efficient transient transfection agent is required. In many cell culture experiments, electroporation has been widely used for ZFN transfection (Table 1). Several less frequently used alternatives have also been used, including adenoviruses, adeno-associated viruses, lentiviruses (IDLV), and lipofectamine 2000. Most of the carriers for ZFN have been used without any obvious unwanted phenotypic changes attributed to the carriers.

Nevertheless, one has to be cautious regardless of the delivery system. For example, although IDLV integrates at rates in chromosomes similar to naked DNA (94), the virus in combination with ZF integrates at a discernibly higher rate (95). In addition, enhanced incorporation of exogenous DNA at off-target sites with “naked DNA” has also been reported with agents that promote double-stranded DNA breaks (96, 97). Increased insertion of the donor or vector DNA has not always been observed and this variability may be attributed to the specificity of ZFN and the repair system of the cell (87, 98). If the goal of the investigator is to knockout a gene, then delivery of mRNA encoding ZFN would prevent the off-target integration from the vector DNA. Although ZFN mRNA has only been delivered by microinjection of embryos (25, 68, 99, 100), several non-viral delivery systems (liposomal, electroporation, peptide, hydrodynamic) could easily be adapted to deliver the ZFN mRNA to other cells (101–103).

Three approaches have been developed to exploit ZFN technology in animal models (Fig. 2). First, embryonic microinjection followed by implantation or SCNT has demonstrated effective gene addition in insects, zebrafish, and mammals (25, 65, 70, 75, 77). Although these techniques will continue to be utilized to develop important animal models, they are unlikely to be used in humans based on technical and ethical grounds. Second, whereas HIV resistance is observed by autologous ZFN-modified CD4⁺ T cells and CD34⁺ human stem cell transplants (56, 61), use of these ZFN-treated cells *ex vivo* is limited to specific infectious diseases and heritable disorders. Nevertheless, the *ex vivo* approach has tremendous promise for treatment or correction of these diseases. Several vectors have been used for *ex vivo* therapy, including non-integrating lentiviruses and electroporation. Third, for *in vivo* delivery, AAV is particularly attractive for gene therapy as demonstrated by the pre-clinical trial of hemophilia. Nevertheless, integration of AAV in the genome is of concern, even though the preclinical study did not reveal an increased insertion of AAV compared to the control AAV without the ZFN construct (87).

While the hydrodynamic delivery method has not been applied to ZFN-directed therapy, the computer-assisted hydrodynamic method is highly efficient and safe for delivery to the liver, and this approach may have significant utility with ZFNs in treating various diseases of the liver (104, 105). Despite the potential utility of hydrodynamic and possibly electroporation approaches, most non-viral methods such as liposomal or peptide delivery technologies may not currently be successful for *in vivo* application of the ZFN technology due to lower transfection levels (106–108). Compared to RNAi therapies, this is a potential disadvantage of plasmid-based ZFNs since many non-viral delivery carriers of siRNA have been effective *in vivo* at least in preclinical trials. That said, there have been significant advances in packaging, targeting and/or extending the circulatory half-life of non-viral nucleic acid

carriers (109–114). For instance, dual-targeting nanoparticles have recently been found to be significantly more effective carriers of plasmids compared to single-targeting or the pegylated control formulations (113). These advancements offer the expectation that non-viral carriers, if not now, will in the future be effective carriers of ZFNs for *in vivo* applications.

Specificity and Off-Target Effect

As the title of the review article (115) states, “It is all about the Specificity.” The importance of ZFN as a therapeutic agent is dependent on its specificity, particularly for *ex vivo* and *in vivo* applications. Since untoward events in SCID-diseased individuals who developed leukemia as a result of retroviral therapy (116), reduction of off-target effects and increased specificity of the ZFN has assumed greater importance. Although increased ZFN specificity is expected to enhance the frequency of gene modification and minimize off-target effects (117), consideration about specificity depends on the method of delivery, the particular target and organism, and the off-target generated. Selection strategies for ZFN that we discussed in the previous section have markedly increased the affinity and specificity of the DNA binding domain to the target sequence.

Several additional studies have exploited approaches aimed at greater specificity. Self-dimerization of wild-type *FokI* increased off-target effects by potentially increasing the number of DNA binding sites. In order to overcome this problem, creation of *FokI* variants that function as obligate heterodimers that did not self-dimerize markedly reduced non-specific, genome-wide cleavage and genotoxicity (118, 119). In addition to the DNA binding and cleavage domain, the composition and length of inter-domain linkers are essential factors of target site selectivity (120). These specificity-related factors should be characterized and screened to select the optimal ZFN.

Besides the intrinsic ZFN binding affinity, the random integration induced by adeno-associated virus or lenti-viral vectors may be problematic, particularly for delivery *in vivo*. Notably, delivery systems that result in sustained high levels of the ZFN are correlated with non-specific effects (32, 35). Thus, integrating viruses may not be desirable, and more ideal vectors that provide transient high levels of the ZFN are preferable. What defines sufficient levels of ZFN in the nucleus is not totally clear, because the optimal levels of ZFN are likely based on the design of the ZFN, the target chromosomal locus, and the cell.

Cell toxicity and genomic assays are commonly done to evaluate the non-specific targeting of ZFN. Cell toxicity assays have included MTT reduction assay, cell viability, and apoptosis, whereas antibodies to factors (H2AX, p53BP) associated with DNA repair can identify DSB within a specific time window. As the specificity of ZFN has improved, these assays have become less effective and more sensitive assays have been sought. Several more recent assays have utilized bioinformatics to identify and rank similar DNA binding to the intended target sites in which pyro-sequencing or a CEL-1 assays was done to determine unintended DNA incorporation. Although these modalities are useful, they are subject to bias ascertainment. More recently, a genome-wide analysis identified on- and off-target activity by mapping the location of IDLV clustered integration sites (95). Importantly, this study also revealed that off-target site binding and cleavage by ZFN predicted *in silico* did not correlate with the actual cleavage site *in vivo*.

Besides lack of specificity, toxicity can occur due to accumulation of ZFN protein in a dose-dependent manner (121). By linking the N-terminus of ZFN to a destabilization ubiquitin moiety or a modified FKBP12 protein, respectively, the ZFN protein level can be regulated by a proteasome inhibitor or small blocking molecule. As a result, cytotoxicity was significantly reduced in several cell lines without loss of gene targeting efficacy (122).

Another potential problem is an immune reaction to the bacteria-derived *FokI* that may occur with repeated injections in mammalian species.

Conclusion

The low frequency of homologous recombination in cells has presented a significant obstacle to modify until the emergence of ZFN. The proficiency of precise gene modification in plants, insects, and mammals, as well as in human cells has bolstered the use of ZFN in a variety of applications. The difficulty of site-specific ZFN selection and optimization has been at least partially overcome by development and validation of ZFN engineering. Several challenges remain for further study to promote the use of this approach: (i) In contrast to RNAi methods, the ZFN technology cannot be readily used by many laboratories to silence specific targets. As a result, continued expansion of a publicly available database of ZFNs and plasmid constructs, covering genes of particular interests to investigators, is required. (ii) Development of safe and robust viral and non-viral vectors of ZFNs is particularly desirable for *in vivo* use. (iii) Increased efficacy of ZFNs may enable their use on less accessible targets/cells. Implicit in this is a greater understanding of the factors that increase target efficiency and decrease off-target DNA modification. Factors involved with greater gene-specific cleavage can be incorporated into the selection process for optimal ZFN assembly. (iv) Development of improved screening for off-target effect and potential toxicity, particularly for *ex vivo* and *in vivo* applications. With further improvement and addressing the problems associated with ZFN, this approach has considerable promise for biomedical research and gene therapy.

Acknowledgments

The authors thank Dr. Pamela Talalay for her helpful suggestions and careful reading of this manuscript. This work was supported by the National Institutes of Health (R01-CA136938).

References

1. Capecchi MR. Altering the genome by homologous recombination. *Science*. 1989; 244(4910):1288–92. [PubMed: 2660260]
2. Choulika A, Perrin A, Dujon B, et al. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of *Saccharomyces cerevisiae*. *Mol Cell Biol*. 1995; 15(4): 1968–73. [PubMed: 7891691]
3. Cohen-Tannoudji M, Robine S, Choulika A, et al. I-SceI-induced gene replacement at a natural locus in embryonic stem cells. *Mol Cell Biol*. 1998; 18(3):1444–8. [PubMed: 9488460]
4. Jasin M. Genetic manipulation of genomes with rare-cutting endonucleases. *Trends Genet*. 1996; 12(6):224–8. [PubMed: 8928227]
5. Bibikova M, Carroll D, Segal DJ, et al. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. *Mol Cell Biol*. 2001; 21(1):289–97. [PubMed: 11113203]
6. Smith J, Bibikova M, Whitby FG, et al. Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. *Nucleic Acids Res*. 2000; 28(17): 3361–9. [PubMed: 10954606]
7. Gommans WM, McLaughlin PM, Lindhout BI, et al. Engineering zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment. *Mol Carcinog*. 2007; 46(5):391–401. [PubMed: 17186549]
8. Xu GL, Bestor TH. Cytosine methylation targeted to pre-determined sequences. *Nat Genet*. 1997; 17(4):376–8. [PubMed: 9398832]
9. Miller J, McLachlan AD, Klug A. Repetitive zinc-binding domains in the protein transcription factor IIIA from *Xenopus* oocytes. *EMBO J*. 1985; 4(6):1609–14. [PubMed: 4040853]
10. Pellegrino GR, Berg JM. Identification and characterization of “zinc-finger” domains by the polymerase chain reaction. *Proc Natl Acad Sci U S A*. 1991; 88(2):671–5. [PubMed: 1988964]

11. Jacobs GH. Determination of the base recognition positions of zinc fingers from sequence analysis. *EMBO J.* 1992; 11(12):4507–17. [PubMed: 1425585]
12. Pavletich NP, Pabo CO. Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 Å. *Science.* 1991; 252(5007):809–17. [PubMed: 2028256]
13. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. *Proc Natl Acad Sci U S A.* 1996; 93(3):1156–60. [PubMed: 8577732]
14. Dreier B, Fuller RP, Segal DJ, et al. Development of zinc finger domains for recognition of the 5 - CNN-3 family DNA sequences and their use in the construction of artificial transcription factors. *J Biol Chem.* 2005; 280(42):35588–97. [PubMed: 16107335]
15. Pattanayak V, Ramirez CL, Joung JK, et al. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. *Nat Methods.* 8(9):765–70. [PubMed: 2182273]
16. Shimizu Y, Sollu C, Meckler JF, et al. Adding fingers to an engineered zinc finger nuclease can reduce activity. *Biochemistry.* 2011; 50(22):5033–41. [PubMed: 21528840]
17. Guo J, Gaj T, Barbas CF 3rd. Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. *J Mol Biol.* 400(1):96–107. [PubMed: 20447404]
18. Jeggo PA. DNA breakage and repair. *Adv Genet.* 1998; 38:185–218. [PubMed: 9677708]
19. Paques F, Haber JE. Multiple pathways of recombination induced by double-strand breaks in *Saccharomyces cerevisiae*. *Microbiol Mol Biol Rev.* 1999; 63(2):349–404. [PubMed: 10357855]
20. van Gent DC, Hoeijmakers JH, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. *Nat Rev Genet.* 2001; 2(3):196–206. [PubMed: 11256071]
21. Symington LS. Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair. *Microbiol Mol Biol Rev.* 2002; 66(4):630–70. table of contents. [PubMed: 12456786]
22. West SC. Molecular views of recombination proteins and their control. *Nat Rev Mol Cell Biol.* 2003; 4(6):435–45. [PubMed: 12778123]
23. Lee HJ, Kim E, Kim JS. Targeted chromosomal deletions in human cells using zinc finger nucleases. *Genome Res.* 2010; 20(1):81–9. [PubMed: 19952142]
24. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. *Nature.* 2005; 435(7042):646–51. [PubMed: 15806097]
25. Doyon Y, McCammon JM, Miller JC, et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. *Nat Biotechnol.* 2008; 26(6):702–8. [PubMed: 18500334]
26. Herrmann F, Garriga-Canut M, Baumstark R, et al. p53 Gene repair with zinc finger nucleases optimised by yeast 1-hybrid and validated by Solexa sequencing. *PLoS One.* 2011; 6(6):e20913. [PubMed: 21695267]
27. Urnov FD, Rebar EJ, Holmes MC, et al. Genome editing with engineered zinc finger nucleases. *Nat Rev Genet.* 2010; 11(9):636–46. [PubMed: 20717154]
28. Segal DJ, Barbas CF 3rd. Custom DNA-binding proteins come of age: polydactyl zinc-finger proteins. *Curr Opin Biotechnol.* 2001; 12(6):632–7. [PubMed: 11849947]
29. Greisman HA, Pabo CO. A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites. *Science.* 1997; 275(5300):657–61. [PubMed: 9005850]
30. Durai S, Mani M, Kandavelou K, et al. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. *Nucleic Acids Res.* 2005; 33(18):5978–90. [PubMed: 16251401]
31. Joung JK, Ramm EI, Pabo CO. A bacterial two-hybrid selection system for studying protein-DNA and protein-protein interactions. *Proc Natl Acad Sci U S A.* 2000; 97(13):7382–7. [PubMed: 10852947]
32. Meng X, Noyes MB, Zhu LJ, et al. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. *Nat Biotechnol.* 2008; 26(6):695–701. [PubMed: 18500337]
33. Isalan M, Klug A, Choo Y. A rapid, generally applicable method to engineer zinc fingers illustrated by targeting the HIV-1 promoter. *Nat Biotechnol.* 2001; 19(7):656–60. [PubMed: 11433278]

34. Maeder ML, Thibodeau-Beganny S, Osiaik A, et al. Rapid “open-source” engineering of customized zinc-finger nucleases for highly efficient gene modification. *Mol Cell*. 2008; 31(2): 294–301. [PubMed: 18657511]
35. Foley JE, Yeh JR, Maeder ML, et al. Rapid mutation of endogenous zebrafish genes using zinc finger nucleases made by Oligomerized Pool ENgineering (OPEN). *PLoS One*. 2009; 4(2):e4348. [PubMed: 19198653]
36. Sander JD, Dahlborg EJ, Goodwin MJ, et al. Selection-free zinc-finger-nuclease engineering by context-dependent assembly (CoDA). *Nat Methods*. 8(1):67–9. [PubMed: 21151135]
37. Cathomen T, Joung JK. Zinc-finger nucleases: the next generation emerges. *Mol Ther*. 2008; 16(7):1200–7. [PubMed: 18545224]
38. Davis D, Stokoe D. Zinc finger nucleases as tools to understand and treat human diseases. *BMC Med*. 2010; 8:42. [PubMed: 20594338]
39. Sander JD, Maeder ML, Reyon D, et al. ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool. *Nucleic Acids Res*. 38(Web Server issue):W462–8. [PubMed: 20435679]
40. Rebar EJ, Pabo CO. Zinc finger phage: affinity selection of fingers with new DNA-binding specificities. *Science*. 1994; 263(5147):671–3. [PubMed: 8303274]
41. Segal DJ, Dreier B, Beerli RR, et al. Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5'-GNN-3' DNA target sequences. *Proc Natl Acad Sci U S A*. 1999; 96(6):2758–63. [PubMed: 10077584]
42. Dreier B, Beerli RR, Segal DJ, et al. Development of zinc finger domains for recognition of the 5'-ANN-3' family of DNA sequences and their use in the construction of artificial transcription factors. *J Biol Chem*. 2001; 276(31):29466–78. [PubMed: 11340073]
43. Bae KH, Kwon YD, Shin HC, et al. Human zinc fingers as building blocks in the construction of artificial transcription factors. *Nat Biotechnol*. 2003; 21(3):275–80. [PubMed: 12592413]
44. Alwin S, Gere MB, Guhl E, et al. Custom zinc-finger nucleases for use in human cells. *Mol Ther*. 2005; 12(4):610–7. [PubMed: 16039907]
45. Shukla VK, Doyon Y, Miller JC, et al. Precise genome modification in the crop species *Zea mays* using zinc-finger nucleases. *Nature*. 2009; 459(7245):437–41. [PubMed: 19404259]
46. Townsend JA, Wright DA, Winfrey RJ, et al. High-frequency modification of plant genes using engineered zinc-finger nucleases. *Nature*. 2009; 459(7245):442–5. [PubMed: 19404258]
47. Osakabe K, Osakabe Y, Toki S. Site-directed mutagenesis in *Arabidopsis* using custom-designed zinc finger nucleases. *Proc Natl Acad Sci U S A*. 2010; 107(26):12034–9. [PubMed: 20508151]
48. Santiago Y, Chan E, Liu PQ, et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. *Proc Natl Acad Sci U S A*. 2008; 105(15):5809–14. [PubMed: 18359850]
49. Liu PQ, Chan EM, Cost GJ, et al. Generation of a triple-gene knockout mammalian cell line using engineered zinc-finger nucleases. *Biotechnol Bioeng*. 2010; 106(1):97–105. [PubMed: 20047187]
50. Cost GJ, Freyvert Y, Vafiadis A, et al. BAK and BAX deletion using zinc-finger nucleases yields apoptosis-resistant CHO cells. *Biotechnol Bioeng*. 2010; 105(2):330–40. [PubMed: 19777580]
51. Malphettes L, Freyvert Y, Chang J, et al. Highly efficient deletion of FUT8 in CHO cell lines using zinc-finger nucleases yields cells that produce completely nonfucosylated antibodies. *Biotechnol Bioeng*. 2010; 106(5):774–83. [PubMed: 20564614]
52. Porteus MH. Mammalian gene targeting with designed zinc finger nucleases. *Mol Ther*. 2006; 13(2):438–46. [PubMed: 16169774]
53. Moehle EA, Rock JM, Lee YL, et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. *Proc Natl Acad Sci U S A*. 2007; 104(9):3055–60. [PubMed: 17360608]
54. Kandavelou K, Ramalingam S, London V, et al. Targeted manipulation of mammalian genomes using designed zinc finger nucleases. *Biochem Biophys Res Commun*. 2009; 388(1):56–61. [PubMed: 19635463]
55. Kim HJ, Lee HJ, Kim H, et al. Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. *Genome Res*. 2009; 19(7):1279–88. [PubMed: 19470664]

56. Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. *Nat Biotechnol.* 2008; 26(7):808–16. [PubMed: 18587387]
57. Orlando SJ, Santiago Y, DeKolver RC, et al. Zinc-finger nuclease-driven targeted integration into mammalian genomes using donors with limited chromosomal homology. *Nucleic Acids Res.* 2010; 38(15):e152. [PubMed: 20530528]
58. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. *Nat Biotechnol.* 2007; 25(11): 1298–306. [PubMed: 17965707]
59. Hockemeyer D, Soldner F, Beard C, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. *Nat Biotechnol.* 2009; 27(9):851–7. [PubMed: 19680244]
60. Zou J, Maeder ML, Mali P, et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. *Cell Stem Cell.* 2009; 5(1):97–110. [PubMed: 19540188]
61. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. *Nat Biotechnol.* 2010; 28(8):839–47. [PubMed: 20601939]
62. Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. *Cell Stem Cell.* 2009; 5(6):584–95. [PubMed: 19951687]
63. Fung H, Weinstock DM. Repair at single targeted DNA double-strand breaks in pluripotent and differentiated human cells. *PLoS One.* 2011; 6(5):e20514. [PubMed: 21633706]
64. Morton J, Davis MW, Jorgensen EM, et al. Induction and repair of zinc-finger nuclease-targeted double-strand breaks in *Caenorhabditis elegans* somatic cells. *Proc Natl Acad Sci U S A.* 2006; 103(44):16370–5. [PubMed: 17060623]
65. Bibikova M, Golic M, Golic KG, et al. Targeted chromosomal cleavage and mutagenesis in *Drosophila* using zinc-finger nucleases. *Genetics.* 2002; 161(3):1169–75. [PubMed: 12136019]
66. Bibikova M, Beumer K, Trautman JK, et al. Enhancing gene targeting with designed zinc finger nucleases. *Science.* 2003; 300(5620):764. [PubMed: 12730594]
67. Beumer K, Bhattacharyya G, Bibikova M, et al. Efficient gene targeting in *Drosophila* with zinc-finger nucleases. *Genetics.* 2006; 172(4):2391–403. [PubMed: 16452139]
68. Beumer KJ, Trautman JK, Bozas A, et al. Efficient gene targeting in *Drosophila* by direct embryo injection with zinc-finger nucleases. *Proc Natl Acad Sci U S A.* 2008; 105(50):19821–6. [PubMed: 19064913]
69. Bozas A, Beumer KJ, Trautman JK, et al. Genetic analysis of zinc-finger nuclease-induced gene targeting in *Drosophila*. *Genetics.* 2009; 182(3):641–51. [PubMed: 19380480]
70. Geurts AM, Cost GJ, Freyvert Y, et al. Knockout rats via embryo microinjection of zinc-finger nucleases. *Science.* 2009; 325(5939):433. [PubMed: 19628861]
71. Mashimo T, Takizawa A, Voigt B, et al. Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases. *PLoS One.* 2010; 5(1):e8870. [PubMed: 20111598]
72. Carbery ID, Ji D, Harrington A, et al. Targeted genome modification in mice using zinc-finger nucleases. *Genetics.* 2010; 186(2):451–9. [PubMed: 20628038]
73. Meyer M, de Angelis MH, Wurst W, et al. Gene targeting by homologous recombination in mouse zygotes mediated by zinc-finger nucleases. *Proc Natl Acad Sci U S A.* 2010; 107(34):15022–6. [PubMed: 20686113]
74. Cui X, Ji D, Fisher DA, et al. Targeted integration in rat and mouse embryos with zinc-finger nucleases. *Nat Biotechnol.* 2011; 29(1):64–7. [PubMed: 21151125]
75. Flisikowska T I, Thorey S, Offner S, et al. Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. *PLoS One.* 2011; 6(6):e21045. [PubMed: 21695153]
76. Hauschild J, Petersen B, Santiago Y, et al. Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases. *Proc Natl Acad Sci U S A.* 2011; 108(29):12013–7. [PubMed: 21730124]
77. Yang D, Yang H, Li W, et al. Generation of PPARgamma mono-allelic knockout pigs via zinc-finger nucleases and nuclear transfer cloning. *Cell Res.* 2011; 21(6):979–82. [PubMed: 21502977]

78. Yu S, Luo J, Song Z, et al. Highly efficient modification of beta-lactoglobulin (BLG) gene via zinc-finger nucleases in cattle. *Cell Res.* 2011; 21(11):1638–40. [PubMed: 21912434]
79. Anderson J, Banerjee A, Akkina R. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. *Oligonucleotides.* 2003; 13(5):303–12. [PubMed: 15000821]
80. Anderson J, Banerjee A, Planelles V, et al. Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. *AIDS Res Hum Retroviruses.* 2003; 19(8):699–706. [PubMed: 13678472]
81. Bai J, Gorantla S, Banda N, et al. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. *Mol Ther.* 2000; 1(3):244–54. [PubMed: 10933940]
82. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. *Sci Transl Med.* 2010; 2(36):36ra43.
83. Wilen CB, Wang J, Tilton JC, et al. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. *PLoS Pathog.* 2011; 7(4):e1002020. [PubMed: 21533216]
84. Sebastiano V, Maeder ML, Angstman JF, et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. *Stem Cells.* 2011; 29(11):1717–26. [PubMed: 21898685]
85. Zou J, Mali P, Huang X, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. *Blood.* 2011; 118(17):4599–608. [PubMed: 21881051]
86. Zou J, Sweeney CL, Chou BK, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. *Blood.* 2011; 117(21):5561–72. [PubMed: 21411759]
87. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. *Nature.* 2011; 475(7355):217–21. [PubMed: 21706032]
88. Weller M, Malipiero U, Groscurth P, et al. T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-beta 2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. *Exp Cell Res.* 1995; 221(2):395–403. [PubMed: 7493639]
89. Gorman AM, Hirt UA, Orrenius S, et al. Dexamethasone pre-treatment interferes with apoptotic death in glioma cells. *Neuroscience.* 2000; 96(2):417–25. [PubMed: 10683582]
90. Kahlon KS, Brown C, Cooper LJ, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. *Cancer Res.* 2004; 64(24):9160–6. [PubMed: 15604287]
91. Reik, A.; Zhou, Y.; Hamlett, A., et al. Zinc Finger Nucleases Targeting the Glucocorticoid Receptor Allow IL-13 Zetakine Transgenic CTLs To Kill Glioblastoma Cells In Vivo in the Presence of Immunosuppressing Glucocorticoids. *Molecular Therapy*; 11th Annual Meeting of the American Society of Gene Therapy; 2008; Boston, MA.
92. Cradick TJ, Keck K, Bradshaw S, et al. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. *Mol Ther.* 2010; 18(5):947–54. [PubMed: 20160705]
93. Nain V, Sahi S, Verma A. CPP-ZFN: a potential DNA-targeting anti-malarial drug. *Malar J.* 2010; 9:258. [PubMed: 20846404]
94. Banasik MB, McCray PB Jr. Integrase-defective lentiviral vectors: progress and applications. *Gene Ther.* 17(2):150–7. [PubMed: 19847206]
95. Gabriel R, Lombardo A, Arens A, et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. *Nat Biotechnol.* 2011; 29(9):816–23. [PubMed: 21822255]
96. Olsen PA, Gelazauskaite M, Randol M, et al. Analysis of illegitimate genomic integration mediated by zinc-finger nucleases: implications for specificity of targeted gene correction. *BMC Mol Biol.* 11:35. [PubMed: 20459736]
97. Miller DG, Petek LM, Russell DW. Adeno-associated virus vectors integrate at chromosome breakage sites. *Nat Genet.* 2004; 36(7):767–73. [PubMed: 15208627]

98. Gellhaus K, Cornu TI, Heilbronn R, et al. Fate of recombinant adeno-associated viral vector genomes during DNA double-strand break-induced gene targeting in human cells. *Hum Gene Ther.* 21(5):543–53. [PubMed: 20021219]
99. McCammon JM, Doyon Y, Amacher SL. Inducing high rates of targeted mutagenesis in zebrafish using zinc finger nucleases (ZFNs). *Methods Mol Biol.* 770:505–27. [PubMed: 21805278]
100. Ochiai H, Fujita K, Suzuki K, et al. Targeted mutagenesis in the sea urchin embryo using zinc-finger nucleases. *Genes Cells.* 15(8):875–85. [PubMed: 20604805]
101. Ejleskar K, Fransson S, Zaibak F, et al. Method for efficient transfection of in vitro-transcribed mRNA into SK-N-AS and HEK293 cells: difference in the toxicity of nuclear EGFP compared to cytoplasmic EGFP. *Int J Mol Med.* 2006; 17(6):1011–6. [PubMed: 16685409]
102. Rejman J, Tavernier G, Bavarsad N, et al. mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. *J Control Release.* 147(3):385–91. [PubMed: 20708647]
103. Williams DJ, Puhl HL, Ikeda SR. A Simple, Highly Efficient Method for Heterologous Expression in Mammalian Primary Neurons Using Cationic Lipid-mediated mRNA Transfection. *Front Neurosci.* 4:181. [PubMed: 21267423]
104. Kamimura K, Suda T, Xu W, et al. Image-guided, lobe-specific hydrodynamic gene delivery to swine liver. *Mol Ther.* 2009; 17(3):491–9. [PubMed: 19156134]
105. Suda T, Suda K, Liu D. Computer-assisted hydrodynamic gene delivery. *Mol Ther.* 2008; 16(6):1098–104. [PubMed: 18398428]
106. Xu M, Kumar D, Srinivas S, et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. *Hum Gene Ther.* 1997; 8(2):177–85. [PubMed: 9017421]
107. Leng Q, Woodle MC, Lu PY, et al. Advances in Systemic siRNA Delivery. *Drugs Future.* 2009; 34(9):721. [PubMed: 20161621]
108. Leng Q, Scaria P, Lu P, et al. Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts. *Cancer Gene Ther.* 2008; 15(8):485–95. [PubMed: 18483501]
109. Bartlett DW, Davis ME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. *Bioconjug Chem.* 2007; 18(2):456–68. [PubMed: 17326672]
110. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. *Mol Ther.* 2008; 16(5):942–6. [PubMed: 18388916]
111. Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. *ACS Nano.* 5(6):5202–13. [PubMed: 21627074]
112. Chou ST, Leng Q, Scaria P, et al. Selective modification of HK peptides enhances siRNA silencing of tumor targets in vivo. *Cancer Gene Ther.* 18(10):707–16. [PubMed: 21818135]
113. Nie Y, Schaffert D, Rodl W, et al. Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy. *J Control Release.* 152(1):127–34. [PubMed: 21392549]
114. Knorr V, Ogris M, Wagner E. An acid sensitive ketal-based polyethylene glycol-oligoethylenimine copolymer mediates improved transfection efficiency at reduced toxicity. *Pharm Res.* 2008; 25(12):2937–45. [PubMed: 18751876]
115. Handel EM, Cathomen T. Zinc-finger nuclease based genome surgery: it's all about specificity. *Curr Gene Ther.* 11(1):28–37. [PubMed: 21182467]
116. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. *N Engl J Med.* 363(4):355–64. [PubMed: 20660403]
117. Cornu TI, Thibodeau-Beganny S, Guhl E, et al. DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. *Mol Ther.* 2008; 16(2):352–8. [PubMed: 18026168]
118. Miller JC, Holmes MC, Wang J, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. *Nat Biotechnol.* 2007; 25(7):778–85. [PubMed: 17603475]
119. Ramalingam S, Kandavelou K, Rajenderan R, et al. Creating designed zinc-finger nucleases with minimal cytotoxicity. *J Mol Biol.* 2011; 405(3):630–41. [PubMed: 21094162]

120. Handel EM, Alwin S, Cathomen T. Expanding or restricting the target site repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant of target site selectivity. *Mol Ther.* 2009; 17(1):104–11. [PubMed: 19002164]
121. Gupta A, Meng X, Zhu LJ, et al. Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases. *Nucleic Acids Res.* 2011; 39(1):381–92. [PubMed: 20843781]
122. Pruett-Miller SM, Reading DW, Porter SN, et al. Attenuation of zinc finger nuclease toxicity by small-molecule regulation of protein levels. *PLoS Genet.* 2009; 5(2):e1000376. [PubMed: 19214211]
123. Goldberg AD, Banaszynski LA, Noh KM, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. *Cell.* 2010; 140(5):678–91. [PubMed: 20211137]

Fig. 1. The components and mechanisms of Zinc Finger Nuclease (ZFN)

ZFN is composed of a three-finger binding domain and a *FokI* nuclease cleavage domain that are connected by a linker. Each finger binds to three base pairs. Site-specific double strand break (DSB) can be induced by ZFN at endogenous loci. The repair process leads to small gene deletions or insertions in non-homologous end joining (NHEJ) pathway. Corrected-gene or transgene (one or multiple) can be integrated into the mutant gene by an alternative mechanism, homology-directed repair (HDR), while co-expressing ZFN and donor DNA.

Fig. 2. Therapeutic applications of ZFN

Three general strategies have been used to deliver ZFN in animal models. Upper, gene-modified offspring can be generated by directly injecting ZFN encoded DNA or mRNA into the embryos followed by implantation in foster mothers. Middle, human T cells or stem cells modified by ZFN *ex vivo* can then be transplanted to an animal model. Lower, ZFN can be delivered to the target cells to correct mutant genes by using adeno-associated virus (AAV) as a vector.

Table 1

ZFN-mediated Gene modification *In vitro*

Cell line	Target gene	Selection	Mechanism	Transfection	Ref.
CHO cells	<i>DHFR</i>	2 + 2	NHEJ	Electroporation	(48)
	<i>BAK/BAX</i>	2 + 2	NHEJ	Electroporation	(50)
	<i>DHFR/GS/FUT8</i>	2 + 2	NHEJ	Electroporation	(49)
	<i>FUT8</i>	2 + 2	NHEJ	Electroporation	(51)
HEK293	<i>GS/BAK</i>	2 + 2	HDR/NHEJ	Electroporation	(57)
	<i>IL2R-</i>	2 + 2	HDR	Lipofectamine/Electroporation	(24)
	<i>-globin/IL2R- /CD8</i>	Modular assembly	HDR	Electroporation	(52)
	<i>VEGF/HoxB13/CFTR</i>	OPEN	NHEJ	Electroporation	(34)
	<i>CCR5</i>	2 + 2	NHEJ	Electroporation	(54)
	<i>CCR5</i>	Modular assembly	NHEJ	Lipofectamine	(55)
	<i>erbB2/BCR-ABL/HIV^Δ</i>	Context	HDR	Calcium phosphate precipitation	(117)
K562	<i>IL2R-</i>	2 + 2	HDR	Lipofectamine/Electroporation	(24), (53)
	<i>VEGF/IL2R-</i>	OPEN	NHEJ	Electroporation	(34)
	<i>IL2R-</i>	2 + 2	HDR	IDLV	(58)
Human T cells	<i>IL2R-</i>	2 + 2	HDR	Electroporation	(24)
	<i>CCR5</i>	2 + 2	NHEJ	Electroporation	(56)
	<i>CXCR4</i>	2 + 2	NHEJ	Ad5/F35	(83)
Human lymphoblastoid cells	<i>IL2R-</i>	2 + 2	HDR	IDLV	(58)
Mouse ESC	<i>H3f3b</i>	2 + 2	HDR	Electroporation	(123)
Human ESCs	<i>IL2R- /CCR5</i>	2 + 2	HDR	IDLV	(58)
	<i>OCT4/AAVS1</i>	2 + 2	HDR	Electroporation	(59)
	<i>PIG-A</i>	OPEN	HDR	Electroporation	(60)
	<i>CCR5</i>	2 + 2	NHEJ	Electroporation	(61)
Human iPSCs	<i>PITX3</i>	2 + 2	HDR	Electroporation	(59)
	<i>PIG-A</i>	OPEN	HDR	Electroporation	(60)
	<i>AAVS1</i>	2 + 2	HDR	Electroporation	(86)
	<i>-globin</i>	OPEN	HDR	Electroporation	(84)

Cell line	Target gene	Selection	Mechanism	Transfection	Ref.
	-globin	2 + 2	HDR	Electroporation	(85)
In vivo					
Organism	Target gene	Selection	Mechanism	ZFN Delivery (Treatment)	Ref.
Drosophila	<i>yellow</i>	Modular assembly	NHEJ	Embryonic microinjection	(65)
	<i>yellow</i>	Modular assembly	HDR	Embryonic microinjection	(66)
	<i>rosy/brown</i>	Modular assembly	NHEJ/HDR	Embryonic microinjection	(67)
	<i>coil/pink</i>	Modular assembly	NHEJ/HDR	Embryonic microinjection	(68)
Zebrafish	<i>kdr</i>	Context	NHEJ	Embryonic microinjection	(32)
	<i>gol/nl</i>	2 + 2	NHEJ	Embryonic microinjection	(25)
	<i>tfr2/dad/telomerase/hif1aa/g ridlock</i>	OPEN	NHEJ	Embryonic microinjection	(35)
	<i>actn1</i> [¶]	CoDA	NHEJ	Embryonic microinjection	(36)
Rats	<i>IgM/Rab38</i>	2 + 2	NHEJ	Embryonic microinjection	(70)
	<i>IL2R-</i>	2 + 2	NHEJ	Embryonic microinjection	(71)
Mice	<i>Mdr1a/PXR</i>	2 + 2	HDR	Embryonic microinjection	(74)
	<i>Mdr1a/Jag1/N otch3</i>	2 + 2	NHEJ	Embryonic microinjection	(72)
	<i>Rosa26</i>	2 + 2	HDR	Embryonic microinjection	(73)
	<i>CCR5</i>	2 + 2	NHEJ	Electroporation (Ex vivo treated human T cells)	(56)
	<i>CCR5</i>	2 + 2	NHEJ	Electroporation (Ex vivo treated human stem cells)	(61)
	<i>CXCR4</i>	2 + 2	NHEJ	Ad5/F35 (Ex vivo treated human T cells)	(83)
	<i>hF9</i>	2 + 2	HDR	AAV	(87)
	<i>IgM</i>	2 + 2	HDR	Embryonic microinjection	(75)
Rabbits	<i>Ppar-</i>	2 + 2	NHEJ	Embryonic microinjection (SCNT)	(77)
Pigs	<i>GGTA1</i>	2 + 2	NHEJ	Electroporation (SCNT)	(76)
Cattles	<i>BLG</i>	2 + 2	NHEJ	Electroporation (SCNT)	(78)

Abbreviations: AAV, adeno-associated virus; Ad5, adenovirus, subtype 5; Ad5/F35, chimeric adenovirus; *actn1*, actinin alpha 1; *BLG*, beta-lactoglobulin; *CFTR*, cystic fibrosis transmembrane conductance regulator; *DHFR*, dihydrofolate reductase; *FUT8*, d-1,6-fucosyltransferase; *GGTA1*, alpha 1-3-galactosyltransferase; *GS*, glutamine synthetase; HDR, homologous DNA repair; hF9, human factor 9; IDLV, integrase-defective lentiviral vector; *IL2R-*, interleukin-2 receptor; KDR, kinase insert domain receptor; NHEJ, error-prone non-homologous end-joining; *PPAR-*, peroxisome-proliferator activator receptor-; SCNT, somatic cell nuclear transfer; *VEGF*, vascular endothelial growth factor.

[§] Retroviruses or plasmids containing ZFN-target sequences for erbB2, BCR-ABL translocation sequence, or the human immunodeficiency virus-1 promoter(HIV) were introduced into 293 cells.

actn1 was one of the 8 genes targeted in zebrafish that had success rate of greater than 1%.